COVID-19 and its long-term sequelae: what do we know in 2023?

Area of Science:

• Infectious Diseases
• Post-viral Syndromes
• Public Health

Background:

• Post-viral syndromes are recognized sequelae following acute viral infections, impacting physical, cognitive, and emotional well-being.
• COVID-19, caused by SARS-CoV-2, frequently leads to medium- and long-term clinical issues, termed long-COVID.
• Long-COVID is defined as symptoms persisting at least two months after SARS-CoV-2 infection onset, not attributable to other conditions.

Purpose of the Study:

• To define long-COVID and outline its prevalence.
• To identify key symptoms and demographic/clinical predictors of long-COVID.
• To highlight challenges and approaches in managing long-COVID.

Main Methods:

• Literature review and synthesis of existing global analyses on long-COVID prevalence.
• Analysis of reported symptoms and identified demographic and clinical predictors.
• Discussion of current understanding of long-COVID's complex nature and management.

Main Results:

• Long-COVID prevalence ranges from 9% to 63%, significantly higher than other post-viral conditions.
• Common symptoms include fatigue, dyspnea, cognitive impairment (brain fog), and post-exertional malaise.
• Predictors include female sex, older age, smoking, comorbidities, unvaccinated status, and severe acute COVID-19.

Conclusions:

• Long-COVID is a complex condition with a wide range of symptoms and significant prevalence.
• Identifying predictors aids in risk stratification and understanding disease mechanisms.
• Integrated, multidisciplinary management tailored to individual patient needs is crucial for effective care.